Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices 14843 

instructions provided at the ‘‘Submit a 

Comment’’ screen. Please include your 

name, company name (if any), and 

‘‘Information Collection 3090–0291, 

FSRS Registration Requirements for 

Prime Grant Awardees on your attached 

document. If your comment cannot be 

submitted using regulations.gov, call or 

email the points of contact in the FOR

FURTHER INFORMATION CONTACT section of 

this document for alternate instructions. 

Instructions: Please submit comments 

only and cite Information Collection 

3090–0291, FSRS Registration 

Requirements for Prime Grant 

Awardees, in all correspondence related 

to this collection. Comments received 

generally will be posted without change 

to regulations.gov, including any 

personal and/or business confidential 

information provided. To confirm 

receipt of your comment(s), please 

check regulations.gov, approximately 

two-to-three days after submission to 

verify posting. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Salomeh Ghorbani, Director, IAE 

Outreach and Stakeholder Engagement 

Division, at 703–605–3467 or IAE_

Admin@gsa.gov. 

SUPPLEMENTARY INFORMATION: 

A. Purpose

The Federal Funding Accountability

and Transparency Act (Pub. L. 109–282, 

as amended by section 6202(a) of Pub. 

L. 110–252), known as FFATA or the

Transparency Act, requires information

disclosure of entities receiving Federal

financial assistance through Federal

awards such as Federal contracts, subcontracts, grants and sub-grants, FFATA

2(a),(2),(i),(ii). The system that collects

this information is called the FFATA

Sub-award Reporting System (FSRS,

www.fsrs.gov). This information

collection requires information

necessary for prime awardee registration

in FSRS to create a user log-in and

enable sub-award reporting for their

entity. To register in FSRS for a user login, an entity is required to provide their

Unique Entity Identifier (UEI). FSRS

then pulls core data about the entity

from their System for Award

Management (SAM) registration to

include the legal business name,

physical address, mailing address and

Commercial and Government Entity

(CAGE) code. The entity completes the

FSRS registration by providing contact

information within the entity for

approval.

If a prime awardee has already 

registered in FSRS to report contractsrelated Transparency Act financial data, 

a new log-in will not be required. In 

addition, if a prime awardee had a user 

account in the Electronic Subcontract 

Reporting System (eSRS), a new log-in 

will not be required. 

B. Annual Reporting Burden

Respondents: 2,488.

Responses per Respondent: 1.

Total Annual Responses: 2,488.

Hours per Response: .5.

Total Burden Hours: 1,244.

C. Public Comments

Public comments are particularly

invited on: Whether this collection of 

information is necessary, whether it will 

have practical utility; whether our 

estimate of the public burden of this 

collection of information is accurate, 

and based on valid assumptions and 

methodology; ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and ways in 

which we can minimize the burden of 

the collection of information on those 

who are to respond, through the use of 

appropriate technological collection 

techniques or other forms of information 

technology. 

Obtaining Copies of Proposals: 

Requesters may obtain a copy of the 

information collection documents from 

the General Services Administration, 

Regulatory Secretariat Division (MVCB), 

1800 F Street NW, Washington, DC 

20405, telephone 202–501–4755. Please 

cite OMB Control No. 3090–0291, FSRS 

Registration Requirements for Prime 

Grant Awardees, in all correspondence. 

Joanne Sosa, 

Acting Director, Regulatory Secretariat 

Division, General Services Administration. 

[FR Doc. 2024–04260 Filed 2–28–24; 8:45 am] 

BILLING CODE 6820–WY–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–OH–24–001, National Center for 

Construction Safety and Health 

Research and Translation. 

Dates and Times: May 13, 2024, 11 

a.m.–6 p.m., EDT; and May 14, 2024, 1

p.m.–6 p.m., EDT.

Place: Video-Assisted Meeting.

Agenda: To review and evaluate grant

applications. 

For Further Information Contact: Dan 

Hartley, Ed.D., Scientific Review 

Officer, Office of Extramural Programs, 

National Institute for Occupational 

Safety and Health, Centers for Disease 

Control and Prevention, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505. Telephone: (304) 285– 

5812; Email: DHartley@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04211 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 


khammond on DSKJM1Z7X2PROD with NOTICES
14844 Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–IP–24–017, Collaborative Research 

on Influenza and Other Respiratory 

Pathogens in South Africa; and RFA–IP– 

24–081, Public Health Epidemiology, 

Prevention and Control of Influenza and 

Other Respiratory Pathogens in China. 

Date: May 17, 2024. 

Time: 10 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H24–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 

718–8833; Email: GAnderson@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04198 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

In accordance with 5 U.S.C. 1009(d), 

the Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. 

Name of Committee: Safety and 

Occupational Health Study Section 

(SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH). 

Dates: June 4–5, 2024. 

Times: 11 a.m.–5 p.m., EDT. 

Place: Teleconference. 

Agenda: The meeting will convene to 

address matters related to the conduct of 

Study Section business and for the 

Study Section to consider safety and 

occupational health-related grant 

applications. 

For Further Information Contact: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 

1095 Willowdale Road, Morgantown, 

West Virginia 26506. Telephone: (304) 

285–5951; Email: MGoldcamp@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04200 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the CDC/HRSA Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) and the Health 

Resources and Services Administration 

(HRSA) announce the following meeting 

of the CDC/HRSA Advisory Committee 

on HIV, Viral Hepatitis and STD 

Prevention and Treatment (CHAC). This 

meeting is open to the public, limited 

only by the number of audio and web 

conference lines (1,000 lines are 

available). Time will be available for 

public comment (registration is required 

to provide oral comment). 

DATES: The meeting will be held on 

April 9 and 10, 2024, from 9 a.m. to 4:30 

p.m., EDT. 

Written comments must be submitted 

by April 19, 2024. Registration to make 

oral comments must be submitted by 

March 26, 2024. 

ADDRESSES: The telephone access 

number is 1–669–254–5252, Webinar 

ID: 160 972 1316, and the Passcode is 

08044152. The web conference access is 

https://cdc.zoomgov.com/j/1609721316?

pwd=cUVqdUp5dlBNaDhhWER

rcWdXUk9yUT09, and the Passcode is 

dx%cJGp3. The number of available 

audio and web conference lines is 1,000. 

FOR FURTHER INFORMATION CONTACT: 

Marah Condit, M.S., Committee 

Management Lead, Office of Policy, 

Planning, and Partnerships, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop US8–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 

639–3423; Email: nchhstppolicy@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The CDC/HRSA Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment (CHAC) 

is charged with advising the Secretary of 

Health and Human Services; the 

Director, Centers for Disease Control 

and Prevention (CDC); and the 

Administrator, Health Resources and 

Services Administration (HRSA), 

regarding objectives, strategies, policies, 

and priorities for HIV, viral hepatitis, 

and STD prevention and treatment 

efforts including (1) surveillance; (2) 

epidemiologic, behavioral, health 

services, and laboratory research; (3) 

identification of policy issues and 

opportunities related to prevention and 

treatment including but not limited to 

professional education, healthcare 

delivery, social determinants of health, 

research, and prevention and treatment 

services; (4) strategic issues influencing 

the ability of CDC and HRSA to fulfill 

their missions; (5) development and 

implementation of federal programs 

focused on prevention and treatment; 

and (6) provide support to the agencies 

in their response to emerging health 

needs. 

Matters to be Considered: The agenda 

will include discussions on (1) 

syndemic approach to testing, (2) using 

prescription data to support the HIV 

care continuum, (3) HIV and aging, (4) 

an update on DoxyPEP, (5) advancing 

diagnosis of hepatitis C virus infection, 

(6) an update from the Long-Acting 

Injectable Workgroup, (7) an update 

from the Community Partnerships 

Workgroup, (8) an update from the 


khammond on DSKJM1Z7X2PROD with NOTICES